» Articles » PMID: 29731916

An Indel Polymorphism in the 3' Untranslated Region of Confers Risk for Hepatocellular Carcinoma Possibly by Regulating Transcriptional Activity in a Chinese Population

Overview
Journal Oncol Lett
Specialty Oncology
Date 2018 May 8
PMID 29731916
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

The purpose of the present study was to assess whether the rs112395617 polymorphism located in the Janus kinase 1 () 3' untranslated region (3' UTR) was associated with the risk of hepatocellular carcinoma (HCC), and to explore the potential mechanism of action. Genomic DNA was extracted from peripheral blood of 290 patients with HCC and 320 controls. A polymerase chain reaction-polyacrylamide gel electrophoresis assay was used to genotype the rs112395617 polymorphism. Quantitative (q)PCR was used to detect the genotype-phenotype association between HCC tissues and different genotypes. Vectors containing the insertion (ins)/ins or deletion (del)/del genotype of the rs112395617 polymorphism were constructed, and the luciferase assay was used to detect the transcriptional activity affected by the rs112395617 polymorphism. It was identified that, when compared with the ins/ins genotype, the del/del and del/ins genotypes of rs112395617 were significantly associated with a decreased risk of HCC. The qPCR results demonstrated that the mRNA expression level with ins/ins and ins/del genotypes was increased by 3.36 and 1.75-fold compared with the del/del genotype in human HCC tissue samples. In addition, the 'AATT' insertion allele of rs112395617 disrupted the binding site for microRNA (miR)-431-5p, thereby increasing transcription . These data suggest that the rs112395617 polymorphism may contribute to HCC susceptibility, in full or at least partially through an effect on transcriptional activity by disrupting its binding with miR-431-5p.

Citing Articles

RNA regulatory mechanisms that control antiviral innate immunity.

Gokhale N, Smith J, Van Gelder R, Savan R Immunol Rev. 2021; 304(1):77-96.

PMID: 34405416 PMC: 8616819. DOI: 10.1111/imr.13019.

References
1.
Wilks A, Harpur A, Kurban R, Ralph S, Zurcher G, Ziemiecki A . Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol. 1991; 11(4):2057-65. PMC: 359893. DOI: 10.1128/mcb.11.4.2057-2065.1991. View

2.
McClune A, Tong M . Chronic hepatitis B and hepatocellular carcinoma. Clin Liver Dis. 2010; 14(3):461-76. DOI: 10.1016/j.cld.2010.05.009. View

3.
Kanaan Z, Roberts H, Eichenberger M, Billeter A, Ocheretner G, Pan J . A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. Ann Surg. 2013; 258(3):400-8. DOI: 10.1097/SLA.0b013e3182a15bcc. View

4.
Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S . Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011; 10(2):127-40. DOI: 10.1038/nrd3264. View

5.
Murphy D, Detjen K, Welzel M, Wiedenmann B, Rosewicz S . Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology. 2001; 33(2):346-56. DOI: 10.1053/jhep.2001.21749. View